Biogen (BIIB) Tops Q2 EPS by $2.22, Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Biogen (BIIB) Call Leaves Tons of Questions, Priority Review Voucher Comment is Negative - Mizuho
July 22, 2020 10:38 AM EDTMizuho Securities analyst Salim Syed weighed on Biogen (NASDAQ: BIIB) saying the Q2 calls leaves room for tons of questions and the priority review voucher comment is telling, in a negative way.
Syed commented, "The Biogen 2Q call just finished... More



